4-[4-（2,3-二氢-1,4-苯并二恶英-6-基）-5-甲基-1H-吡唑-3-基]-6-乙基-1,3-苯二醇 | 171009-07-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-[4-（2,3-二氢-1,4-苯并二恶英-6-基）-5-甲基-1H-吡唑-3-基]-6-乙基-1,3-苯二醇
• 英文名称: 4-[4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethyl-benzene-1,3-diol
• 英文别名: CCT018159；4-[4-(2,3-Dihydro-1,4-benzodioxin-6-YL)-3-methyl-1H-pyrazol-5-YL]-6-ethylbenzene-1,3-diol；4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethylbenzene-1,3-diol
• CAS: 171009-07-7
• 化学式: C₂₀H₂₀N₂O₄
• 分子量: 352.39
• InChiKey: OWPMENVYXDJDOW-UHFFFAOYSA-N

物化性质

• 沸点：
  547.3±50.0 °C(Predicted)
• 密度：
  1.322±0.06 g/cm3(Predicted)
• 溶解度：
  乙醇中≤30mg/ml；DMSO中≤30mg/ml；二甲基甲酰胺中≤30mg/ml

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  87.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-ethyl-7-hydroxy-2-methyl-chromen-4-one 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 4-[4-（2,3-二氢-1,4-苯并二恶英-6-基）-5-甲基-1H-吡唑-3-基]-6-乙基-1,3-苯二醇
  参考文献：
  名称：

  The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors

  摘要：

  High-throughput screening identified the 3,4-diarylpyrazole CCT018159 as a novel and potent (7.1 mu M) inhibitor of Hsp90 ATPase activity. Here, we describe the synthesis of CCT018159 and a number of close analogues together with data on their biochemical properties. Some initial structure-activity relationships are discussed, as well as the crystal structure of CCT018159 bound to Hsp90. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.046

文献信息

• [EN] COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2014079150A1

  公开（公告）日：2014-05-30

  Provided are compounds of formula (I), which can inhibit glutaminase. Pharmaceutical compositions comprising these compounds and uses as glutaminase inhibitors for treating cancers thereof are also provided.

  提供了化合物的化学式(I)，可以抑制谷氨酸酶。还提供了包含这些化合物的药物组合物，并用作抑制谷氨酸酶以治疗相关癌症的用途。
• [EN] CDK4/6 INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS DE CDK4/6 ET LEUR UTILISATION
  申请人：BEIJING XUANYI PHARMASCIENCES CO LTD

  公开号：WO2019035008A1

  公开（公告）日：2019-02-21

  The present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, a solvate, a stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (A) or formula (B), and any subgenera thereof, and use of said compounds and compositions thereof, wherein R1, R2, R3a, R3b, R5, R6, X1, X2, Y and n are described herein.

  本公开涉及式(I)的化合物，或其药用可接受的盐、溶剂合物、立体异构体或互变异构体，包括化合物(A)或化合物(B)的药物组合物，以及所述化合物和组合物的使用，其中R1、R2、R3a、R3b、R5、R6、X1、X2、Y和n如本文所述。
• [EN] PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS<br/>[FR] LACTAMES SUBSTITUÉS PAR HÉTÉROCYCLE PHARMACEUTIQUEMENT UTILES
  申请人：CYLENE PHARMACEUTICALS INC

  公开号：WO2011031979A1

  公开（公告）日：2011-03-17

  The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, infections, and certain immunological disorders.

  这项发明提供了抑制CK2和/或Pim激酶的化合物和含有这些化合物的组合物。这些化合物和组合物可用于治疗癌症等增殖性疾病，以及其他与激酶相关的疾病，包括炎症、疼痛、感染和某些免疫性疾病。
• [EN] COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS ET PROCÉDÉS D'UTILISATION DESDITS COMPOSÉS
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2015143340A1

  公开（公告）日：2015-09-24

  Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.

  本文描述了抑制谷氨酸酶的化合物和组合物。本文还描述了利用这些抑制谷氨酸酶的化合物治疗癌症的方法。
• NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
  申请人：HADDACH Mustapha

  公开号：US20110071136A1

  公开（公告）日：2011-03-24

  The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.

  这项发明提供了抑制CK2和/或Pim激酶的化合物以及含有这些化合物的组合物。这些三环化合物和含有它们的组合物对于治疗增殖性疾病如癌症以及其他与激酶相关的疾病条件包括炎症、疼痛、病原体感染和某些免疫性疾病是有用的。